MA49986A - Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide - Google Patents

Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide

Info

Publication number
MA49986A
MA49986A MA049986A MA49986A MA49986A MA 49986 A MA49986 A MA 49986A MA 049986 A MA049986 A MA 049986A MA 49986 A MA49986 A MA 49986A MA 49986 A MA49986 A MA 49986A
Authority
MA
Morocco
Prior art keywords
processes
rapid flow
via rapid
flow synthesis
oligomers via
Prior art date
Application number
MA049986A
Other languages
English (en)
Inventor
Gunnar J Hanson
Bradley L Pentelute
Mark D Simon
Kyle A Totaro
Ming Zhou
Hong Zong
Original Assignee
Massachusetts Inst Technology
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology, Sarepta Therapeutics Inc filed Critical Massachusetts Inst Technology
Publication of MA49986A publication Critical patent/MA49986A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G79/00Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule
    • C08G79/02Macromolecular compounds obtained by reactions forming a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbon with or without the latter elements in the main chain of the macromolecule a linkage containing phosphorus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/314Phosphoramidates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3233Morpholino-type ring
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00Production
    • C12N2330/30Production chemically synthesised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Luminescent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MA049986A 2017-09-25 2018-09-25 Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide MA49986A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762562741P 2017-09-25 2017-09-25

Publications (1)

Publication Number Publication Date
MA49986A true MA49986A (fr) 2020-07-01

Family

ID=65810587

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049986A MA49986A (fr) 2017-09-25 2018-09-25 Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide

Country Status (7)

Country Link
US (2) US20200362339A1 (fr)
EP (1) EP3672601B1 (fr)
JP (1) JP7218361B2 (fr)
ES (1) ES2963336T3 (fr)
MA (1) MA49986A (fr)
TW (1) TWI812647B (fr)
WO (1) WO2019060862A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060862A1 (fr) 2017-09-25 2019-03-28 Sarepta Therapeutics, Inc. Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
KR20220098217A (ko) * 2019-11-13 2022-07-11 니뽄 신야쿠 가부시키가이샤 올리고 핵산 화합물의 제조 방법
KR102934598B1 (ko) 2020-06-05 2026-03-05 넥스올리고(주) 신규한 몰포리노 올리고뉴클레오티드 유도체
US12378267B2 (en) 2021-06-17 2025-08-05 Entrada Therapeutics, Inc. Synthesis of FMOC-protected morpholino monomers and oligomers
CN119156395A (zh) 2022-04-22 2024-12-17 恩特拉达治疗学股份有限公司 用于递送治疗剂的环肽

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO1986005519A1 (fr) 1985-03-15 1986-09-25 James Summerton Reactif et procede d'analyse de polynucleotides
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
WO1990002749A1 (fr) 1988-09-01 1990-03-22 Forskningscenter Risø Procede de synthese de peptides et support solide de realisation dudit procede
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
PL2735568T3 (pl) * 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
RU2606627C2 (ru) * 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
EP2499248B1 (fr) * 2009-11-13 2017-01-04 Sarepta Therapeutics, Inc. Composé antiviral antisens et méthode de traitement d'une infection par le virus grippal
ES2607603T3 (es) 2010-09-30 2017-04-03 Nippon Shinyaku Co., Ltd. Derivado de ácido morfolino nucleico
JP6496549B2 (ja) 2011-11-30 2019-04-03 サレプタ セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症における誘発されたエクソン包含
US20140315977A1 (en) * 2013-03-14 2014-10-23 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
DK3015467T3 (da) * 2013-05-24 2025-02-10 Ajinomoto Kk Morpholino-oligonukleotidfremstillingsfremgangsmåde
US11236338B2 (en) * 2013-09-05 2022-02-01 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
DK3118311T3 (en) * 2014-03-12 2019-03-11 Nippon Shinyaku Co Ltd Antisense nucleic acid
EP3858993A1 (fr) * 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions et procédés pour le traitement de la dystrophie musculaire de duchenne et de troubles apparentés
MD3464306T2 (ro) * 2016-05-24 2024-08-31 Sarepta Therapeutics Inc Procedee de preparare a oligomerilor morfolino fosforodiamidați
BR112018074346B1 (pt) * 2016-05-24 2023-01-03 Sarepta Therapeutics, Inc. Composto oligomérico e processo para preparar um composto oligomérico
KR102523527B1 (ko) * 2016-06-30 2023-04-20 사렙타 쎄러퓨틱스 인코퍼레이티드 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법
WO2019060862A1 (fr) 2017-09-25 2019-03-28 Sarepta Therapeutics, Inc. Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide

Also Published As

Publication number Publication date
JP7218361B2 (ja) 2023-02-06
EP3672601B1 (fr) 2023-09-13
ES2963336T3 (es) 2024-03-26
TWI812647B (zh) 2023-08-21
US12590306B2 (en) 2026-03-31
EP3672601A4 (fr) 2021-05-12
US20250043283A1 (en) 2025-02-06
WO2019060862A1 (fr) 2019-03-28
EP3672601A1 (fr) 2020-07-01
US20200362339A1 (en) 2020-11-19
JP2020535141A (ja) 2020-12-03
TW201919659A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
EP3672601A4 (fr) Procédés de préparation d'oligomères morpholino phosphorodiamidate par l'intermédiaire d'une synthèse à flux rapide
MA45155A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA45183A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
MA49775A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3980073A4 (fr) Procédés de préparation de complexes protéine-oligonucléotide
GB2567754B (en) Flow path sensing for flow therapy apparatus
EP3307266A4 (fr) Nouvelles polythérapies à base de cannabinoïdes pour le myélome multiple (mm)
EP3302507A4 (fr) Procédés de diagnostic pour thérapie par lymphocytes t
EP3387189A4 (fr) Système pour coordonner des machines de fraisage et de pavage
EP3353278A4 (fr) Préparation d'échantillons pour des types d'échantillons compliqués
MA41962A (fr) Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
DK3609540T5 (da) Fremgangsmåde til immunkonjugatsyntese
EP3509982A4 (fr) Distributeur proactif pour système d'alerte mobile d'opérateur
EP3631564A4 (fr) Système à réalité augmentée à fixation amovible pour lunettes
EP3367890A4 (fr) Procédés de radiothérapie pour déclencher des médicaments à photoactivation
MA45362A (fr) Procédés de préparation d'oligomères morpholino de phosphorodiamidate
EP3360893A4 (fr) Molécule de pdl-1 soluble à forte affinité
EP3500286A4 (fr) Synthèse d'échelle d'elamipretide à base de n-carboxyanhydride
EP3334464A4 (fr) Conjugués chélatés à base de manganèse pour l'imagerie par résonance magnétique moléculaire
EP3837113A4 (fr) Système de positionnement intégré à une machine
PL3609789T3 (pl) Układ pakowania do wytwarzania torebek
EP3766869A4 (fr) Procédé simple de préparation d'avibactam
EP3681697A4 (fr) Supports thermiques pour éléments 3d formés à partir de particules
EP2817473A4 (fr) Appareil pour régler l'alignement de machines à forer
EP3317004A4 (fr) Appareil de préparation d'une solution, et procédés associés